At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
Intravenous insulin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Glycemic Control and Variability for Congestive Heart Failure Exacerbation
In Brief
A Phase 2 clinical trial evaluating Intravenous insulin and Subcutaneous insulin for Congestive Heart Failure and Diabetes Mellitus. Completed, enrolled 75 participants across 1 site.
Detailed Summary
High glucose as well as fluctuations (rapid swings) in blood glucose can contribute to severe hospital complications and even death.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCongestive Heart Failure, Diabetes Mellitus
CountriesUnited States
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartJan 2009
Primary CompletionAug 2012
Study CompletionSep 2013
TodayJul 2026
First PostedDec 22, 2008
Enrollment StartJan 1, 2009
Primary CompletionAug 1, 2012
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 17.5 years ago
Interventions
Intravenous insulindrug
Patients will receive continuous insulin infusion through the vein.
Subcutaneous insulindrug
4 injections of insulin/day